Introduction
Airway smooth muscle controls airway calibre and therefore determines alveolar ventilation. Disease states such as asthma are characterized by an increased muscle tone and airways resistance, which are due, at least in part, to changes in the response of airway smooth muscle to endogenously generated stimuli [ 11. Clearly, an understanding of the physiological and pathophysiological regulation of smooth muscle tone is central to the development of novel therapeutic approaches for the treatment of airway hyper-reactivity.
In this brief review, we attempt to summarize some of the progress that has been made recently in our understanding of phosphoinositide signalling in airway smooth muscle, with a particular emphasis on how changes in cyclic nucleotides and membrane potential may modulate the phosphoinositide cycle.
Contractile agonists and phosphoinositide turnover
Contraction of airway smooth muscle can be provoked by a variety of agents (termed spasmogens) that interact with cell-surface receptors to effect pharmacomechanical coupling [2, 31. Agents may be released endogenously from neurons, may be blood-borne or may be released from pro-inflammatory cells that can infiltrate the airways under Abbreviations used: DAG, diacylglycerol; PI-PLC, phosphoinositide-specific phospholipase C. certain circumstances [4] . Although many spasmogenic agents cause significant depolarization of airway smooth muscle, it is generally considered that it is their ability to stimulate phosphoinositidespecific phospholipase C (PI-PLC), via a guaninenucleotide-binding protein (G-protein), and cause the generation of the second messengers inositol 1,4,5-trisphosphate [Ins ( 1, 4, 5) P3] and diacylglycerol (DAG), which underlies their contractile action [2, Considerable progress has been made in characterizing the array of receptors that can stimulate PI-PIX activity in this tissue. Thus, acetylcholine (via M3) [S] , histamine (via HI) [6] , bradykinin (via B2) [7] , endothelin [8] and a variety of other agents including neuropeptides (for example, tachykinins [9] ) and mediators (for example, leukotrienes [ lo] and thromboxanes [ 111) can all evoke an increase in phosphoinositide turnover in preparations of airway smooth muscle. Although the majority of these receptors appear to recruit G-proteins of the pertussis-toxin-insensitive G, family selectively to stimulate PI-PLC [3, 12, 131, there is evidence that some agents (for example, leukotriene D, [ 101) act via pertussis-toxin-sensitive transduction mechanisms.
In some cases, most notably for M,-muscarinic and HI-histaminergic receptor activation, the time-course, concentration-dependency and pattern of inositol (po1y)phosphate generation has been investigated in some detail. Muscarinic receptor agonists or histamine cause a sustained activation of 31.
PI-PI,C activity, such that, in the presence of a concentration of Li+ that is sufficient to completely prevent inositol monophosphate hydrolysis, linear accumulations of total [ 3H]inositol phosphates can be observed for at least 30 min in my~-[~H]inositollabelled airway smooth muscle preparations [14] [15] [16] . Although the ability of these agonists to cause a sustained activation of phosphoinositide turnover is reflected in the time-course of changes in membrane inositol phospholipids [ 17, 181, only rapid, transient increases in the concentration of Ins( 1,4,5)P3 have been observed [ 16. 18-20] , with cellular levels of this second messenger returning to pre-stimulation levels within 60 s of agonist addition. Therefore, although peak Ins( 1 ,4,5)P3 accumulation precedes initiation of contraction temporally, and is consistent with Ins( 1,4,5)P3 interacting with a specific receptor [21] to induce Caz + mobilization from organellar stores being sufficient and necessary for contraction [22, Thus, agonist-stimulated phosphoinositide turnover provides the second messenger that is responsible for initiating pharmacomechanical coupling, and the sustained activation of this signalling pathway may be important in providing DAG during the maintained tonic phase of contraction.
Cyclic-nucleotide-elevating agents and the phosphoinositide cycle
It has been established for some time that elevations of cyclic AMP or cyclic GMP concentration in airway smooth muscle can cause relaxation of spontaneous and spasmogen-supported tone [ 321. Indeed, the use of P-adrenoceptor agonists to cause bronchodilatation has been a mainstay of asthma therapy for several years [33] . There appears to be no simple correlation between changes in airway smooth muscle cyclic nucleotide levels and relaxation. The observed relaxation has been shown to depend on a number of factors, which include the degree of initial spasmogen-supported tone, the spasmogen used to induce the tone and the concentration and type of cyclic-nucleotide-elevating agent used to cause relaxation . A common,
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although not universal [38] , observation is that cyclic-nucleotide-elevating agents exhibit a decreased potency for relaxation against tone induced by muscarinic receptor agonists compared with that induced by a number of other contractile agonists (see below).
The mechanism by which cyclic-nucleotideelevating agents cause relaxation of airway smooth muscle has been investigated extensively. One key observation that was made only relatively recently, was that, contrary to an earlier report [39] , cyclic-AMP-elevating agents could inhibit spasmogenstimulated phosphoinositide turnover in airway smooth muscle preparations [40, 41] . A striking feature of the results reported by Hall and Hill, and Madison and Brown was that in bovine [40] and canine [4 11 tracheal smooth muscle preparations P-adrenoceptor agonists dramatically and concentration-dependently inhibited (by up to 50-75%) histamine-stimulated total ['H]inositol phosphate accumulation, but were completely ineffective when carbachol or methacholine were used to elicit phosphoinositide turnover. The studies of Madison and Brown [41] and subsequent work by others [42-441 demonstrated that other cyclic-AMPelevating strategies (for example, forskolin, phosphodiesterase inhibition) had similar inhibitory effects. In addition, an inhibitory effect on ['H]inositol phosphate accumulation could be observed when a non-selective phosphodiesterase inhibitor, isobutylmethylxanthine, was used against sub-maximally effective concentrations of muscarinic agonist [43, 441. The differential effects of cyclic-AMPelevating agents on histamine-as against muscarinic cholinoceptor-stimulated phosphoinositide turnover bear a striking resemblance to those reported previously in contractile studies. One possible explanation that has been proposed relates to the large 'receptor reserve' that exists for full muscarinic agonists [45- Airway smooth muscle, in common with a variety of other smooth muscle types, expresses a mixed population of muscarinic receptor subtypes. In addition to the M3-muscarinic receptor population that is responsible for stimulating phosphoinositide turnover, M,-muscarinic receptors are also present [5, 12, and enzymically dissociated cells [47] . Clearly, the presence of M,-muscarink receptors may provide a possible explanation for why muscarinic receptorinduced contraction and/or phosphoinositide turnover shows a decreased susceptibility to inhibition by cyclic-AMP-elevating agents.
A number of experimental approaches have been used in an attempt to establish the relative roles of M,-as against M,-mediated effects in airway smooth muscle. These include exploitation of the fact that M,-mediated effects (but not M,-media- [32, 35, 56, 571 . Perhaps the first attempt to assess whether cyclic-GMPelevating agents could inhibit spasmogen-stimulated phosphoinositide turnover in airway smooth muscle came to a momentous conclusion [58] . Langlands and colleagues [58] reported that increasing cyclic GMP concentration in guinea pig tracheal rings using a cyclic-GMP-specific phosphodiesterase inhibitor (zaprinast) had no significant effect on the rate and extent of contraction induced by histamine or methacholine, but could [43] . Figure 2 illustrates our own complementary data that demonstrate that sodium nitroprusside, an agent that dramatically increases cyclic GMP accumulation via activation of soluble guanylyl cyclase, does not significantly inhibit histamine-stimulated ['H]inositol phosphate accumulation in bovine tracheal smooth muscle. Therefore, although a species difference between guinea pigderived and bovine-derived airway smooth muscle has yet to be excluded, we are confident that the observations of Langlands et al. [58] do not represent a general phenomenon.
Membrane potential and the phosphoinositide cycle
Agents that increase the probability of K + -channel opening cause membrane hyperpolarization of airway smooth muscle and promote relaxation 
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[59-6 11. Furthermore, the ability of K+-channel openers to inhibit agonist-induced bronchospasm in vivo effectively [62] has resulted in considerable interest in the therapeutic potential of this class of agent in the treatment of airway hyperresponsiveness [61] . We have provided evidence recently that BRL 38227, the active ( -) (3S,4R) enantiomer of the prototypic K + -channel opener, cromakalim [63] , can affect agonist-stimulated phosphoinositide turnover in a manner superficially resembling that observed previously for cyclic-AMP-elevating agents [16, Figure 3) . Similar effects can be observed when calcium channel antagonists are used to block Ca2+ entry [16] . These results, together with other data obtained using patch-clamp techniques [29, 301, With respect to the mode of action of K + -channel openers, it is interesting to note that Badrenoceptor agonists also cause membrane hyperpolarization of airway smooth muscle [67] . The evidence available so far suggests that the hyperpolarizing effects of B-adrenoceptor agonists are mediated via a distinct class of K+-channel, high conductance Ca2+-activated K+-channels (&.a [65] ), both via G-protein [68] and via cyclic-AMPdependent protein-kinase-mediated [69] 
Concluding remarks
The data presented above suggest that /?-adrenoceptor agonists and K + -channel openers exert an inhibitory effect on histamine-stimulated phosphoinositide turnover through their common ability to cause membrane hyperpolarization and to limit Ca2+ entry via L-type channels. Spasmogens can activate multiple pathways of Ca2+ entry in airway smooth muscle, and it has yet to be determined whether /?-adrenoceptor agonists or K+-channel openers have any influence on the receptoroperated Ca2+ entry pathway described by Kotlikoff and colleagues [27, 28] . The absolute or relative resistance of muscarinic-receptor-stimulated phosphoinositide turnover to inhibition by /?-adrenoceptor agonists or K+-channel openers respectively remains to be explained fully. That the sustained phase of muscarinic receptor-stimulated phosphoinositide turnover is less dependent on Ca2+ influx, together with the recent evidence that &a channels are inhibited by muscarinic receptor activation via a pertussis-toxin-sensitive pathway [68, 701 may provide at least a partial explanation.
In contrast to the recently described effects of membrane hyperpolarization on agonist-stimulated phosphoinositide turnover in vascular smooth muscle [7 11, it [40] and K + -channel openers [ 161 on histamine-stimulated ['H]inositol phosphate accumulations are seen, and why crosstalk between these two signalling pathways has sometimes not been reported [72] .
The functional consequences of an inhibition of spasmogen-stimulated phosphoinositide turnover that becomes apparent during the sustained phase of airway smooth muscle contraction have yet to be established. Unlike spasmogen-stimulated increases in Ins( 1,4,5)P3, the elevation of DAG appears to be sustained throughout the period of spasmogen challenge [ 171. Thus, it is now important to establish whether the effects of the inhibitory agents described here exert an action at the level of the second messenger in the pathway DAG, before the true importance of such cross-talk mechanisms can be ascertained. There was no significant increase in the maximum response to a-Me-5-HT at any concentration of U46619. These data can be illustrated further in the form of histograms showing the effects of different concentrations of a-Me-5-HT and U466 19, alone and in combination (Figure lb) . This shows that, at lower concentrations only, the effect of these two agents when applied in combination is greater than the simple sum of their individual effects.
The interaction between agonists acting at 5-HT, and at TxA, receptors are consistent with the expectations of threshold synergy [5] . A theoretical model of threshold synergy [7] proposes that if the transduction pathways of different receptors merge, then the model can be used to establish conditions under which agonist-agonist interactions
